bile duct cancer
Relay Therapeutics Licensing FGFR2 Agent to Elevar Therapeutics for $75M
Selling the rights to lirafugratinib will allow Relay to focus on developing its PI3Kα agents.
FDA Approves Roche CDx Test for Use With Jazz Pharmaceuticals Drug in Biliary Tract Cancer
The approval is for a new indication for Roche's existing Pathway HER2 (4B5) test and is intended to identify patients with HER2-positive biliary tract cancer.
Jazz Pharmaceuticals Nabs FDA Accelerated Approval for Ziihera in HER2-Positive Biliary Tract Cancer
The approval is based on the objective response rate in a Phase IIb trial of previously treated, unresectable or metastatic biliary tract cancer patients.
Jazz Pharma Seeking Approval for Zanidatamab in HER2-Positive Biliary Tract Cancer
The application was based on Phase IIb trial results showing a 41 percent response rate on zanidatamab in this setting.
The study didn't meet its prespecified endpoint but suggests potential activity in HER2-amplified urothelial cancer and cholangiocarcinoma.
Jun 3, 2023